A sustained-release lipid pre-concentrate and a sustained-release injectable pharmaceutical composition in the form of lipid solution comprising the same
Controlled-release monolithic matrix tablets comprising bepotastine or its pharmaceutically acceptable salt and process for preparing the same
KR102175201B1
Composition for preventing or treating sensorineural hearing impairment comprising Vaccinium myrtillus extract
KR20200122080A
Composition for preventing or treating refractory cancer comprising Labetalol
KR20200100392A
A sustained-release lipid pre-concentrate and a sustained-release injectable pharmaceutical composition in the form of lipid solution comprising the same
WO2019107859A1
Nano solubilized porous body with dutasteride encapsulated therein, pharmaceutical composition containing same and method of producing same
KR20190109677A
Ophthalmic formulation for preventing or treating dry eye syndrome comprising cevimeline or a pharmaceutically acceptable salt thereof
KR20190049023A
Controlled-release monolithic matrix tablets comprising bepotastine or its pharmaceutically acceptable salt and process for preparing the same
KR101819709B1
Pharmaceutical composition for preventing or treating keratoconjunctivitis sicca comprising sulglycotide or a pharmaceutically acceptable salt thereof
